GEN Exclusives

More »

GEN News Highlights

More »
Sep 26, 2006

Juvaris BioTherapeutics Gets SBIR Grant to Develop AML Vaccine Technology

  • Juvaris BioTherapeutics was awarded a one-year Phase I SBIR grant from the NCI in collaboration with David Claxton, M.D., at Penn State College of Medicine to develop a therapeutic vaccine approach for acute myelogenous leukemia (AML). Juvaris’ vaccine technology will be tested in rodent tumor models to evaluate its impact using an antigen-specific immunotherapeutic AML vaccine (JuvaVax).

    The SBIR grant application was supported by preclinical data generated by Juvaris and Dr. Claxton demonstrating significant protection in a rodent tumor model.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?